C
rohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD), are chronic inflammatory bowel disorders of the gastrointestinal tract with increasing global incidence, particularly in recently industrialized countries. 1, 2 Westernization of diet has been implicated in the pathogenesis of IBD. 3 Nevertheless, epidemiologic studies of diet have yielded very few promising leads.
Increasing consumption of sweetened beverages has been linked to the growing epidemic of obesity and metabolic-related disorders. [4] [5] [6] [7] In parallel, there is mounting evidence for the critical role of obesity in chronic inflammatory disorders of the gastrointestinal tract, particularly CD. [8] [9] [10] In addition, a number of studies have shown a positive association between consumption of sweetened beverages and systemic inflammation as measured by C-reactive protein level. 11, 12 In turn, we previously have shown that higher prediagnostic levels of circulating C-reactive protein are associated with risk of incident CD. 13 A recent study from the European Prospective Investigation into Cancer and Nutrition showed that a dietary pattern consisting of a high consumption of sugar and sweetened beverages and a low consumption of vegetables is associated with an increased risk of UC.
14 Nevertheless, there has been no comprehensive examination of the association between consumption of sweetened beverages and the risk of incident CD and UC.
We therefore sought to examine the association between consumption of sweetened beverages and the risk of CD and UC in 2 large prospective cohort studies in Sweden, the Swedish Mammography Study (SMC) and the Cohort of Swedish Men (CoSM). With detailed and validated data on dietary information on more than 80,000 men and women with linkage to the Swedish Patient Register, these cohorts offered us a unique opportunity to examine this relationship while adjusting for other potential lifestyle and dietary factors.
Methods

Study Population
The SMC is a population-based cohort from the Uppsala county of central Sweden that was established between 1987 and 1990 when 66,651 women returned completed questionnaires on diet, alcohol, weight, height, medication use, and reproductive and menopausal factors. Follow-up questionnaires were sent in 1997, 2008, and 2009 and were expanded to include data on smoking, physical activity, medical history, and family history. The CoSM is a parallel population-based cohort of 45,906 middle-aged and elderly men established in central Sweden (Västmanland and Örebro Counties) in the fall of 1997. At baseline, participants provided information on lifestyle factors such as diet, physical activity, smoking, weight, and use of a number of specified medications through a mailed questionnaire similar to that of the SMC. Follow-up questionnaires were sent to participants in 2008 and 2009. For this study, we included participants who had completed the 1997 questionnaires in both cohorts, which included all participants in the CoSM and women in the SMC who were still alive in 1997 and returned the dietary questionnaire (n ¼ 38,984; 70% response rate). We excluded men and women who did not provide information on diet or those with a diagnosis of IBD at baseline (Figure 1 ). We also excluded participants with implausible total caloric intake defined by intakes not within 3 SDs of the log-transformed mean.
Primary Exposure and Other Covariates
Dietary information was collected using a 96-item Semiquantitative Food Frequency Questionnaire (SFFQ) at baseline in 1997 in both cohorts. The SFFQ specifically asked participants to report their usual consumption, during the past year, of a standard glass (200 mL) of sweetened beverages in the form of soft drinks per day or week. Although in the 1997 questionnaire no distinction was made between sugar-sweetened (Coca Cola, Atlanta, GA, Pepsi, Purchase, NY, and so forth) and artificially sweetened beverages (Diet Coca Cola, Diet Pepsi, and so forth), according to Swedish national consumption data, artificially sweetened soft drinks accounted for less than 10% and 20% of all soft drinks among men and women, respectively. 15 Sweetened beverages also did not include fruit juices, syrups, energy and sports drinks, or sweetened coffee, tea, or milk.
Intakes of nutrients were calculated using composition values from the Swedish Food Administration Database and were adjusted for total caloric intake using the residual model. The SFFQ has been validated against fourteen 24-hour diet recall interviews performed over a 1-year period in a subset of participants in the CoSM (n ¼ 248). The Spearman coefficient correlation ranged between 0.70 and 0.73 for intakes of total carbohydrate, fat, fiber, and sucrose (primary sugar in soft drinks). 16 In the SMC, the SFFQ (version from 1987 was similar to that used in the CoSM and the SMC in 1997) has been validated against four 1-week diet records performed over a 1-year period in 129 women. 17 The Spearman correlation coefficient between the SFFQ and diet records for sweetened beverages was 0.60.
Outcome Ascertainment
The Swedish National Board of Health and Welfare has collected individual-level data on hospital discharges on a countywide level since 1964 (nationwide since 1987). 18 Each record, organized according to an individual's What You Need to Know Background Consumption of sweetened beverage has been associated with systemic inflammation and immunemediated disorders such as rheumatoid arthritis. We analyzed data from 2 large cohorts in Sweden to determine whether consumption was associated with risk of CD or UC.
Findings
We observed no evidence for associations between consumption of sweetened beverages and later risk of CD or UC.
Implications for patient care
Consumption of sweetened beverages does not appear to increase risk of CD or UC. Studies are needed to determine the effects on disease progression in patients who already have these diseases. personal identity number, includes date of birth, sex, dates of hospital admission, hospital department, and discharge diagnoses (including surgical procedures), coded according to the International Classification of Diseases (ICD). 19 Since 2001, this registry was expanded to include specialized outpatient care. 18 Incident cases of CD and UC were identified by linkage of the SMC and the CoSM participants to the nationwide registry. Incident cases were defined by at least 2 inpatient or outpatient encounters with a primary or secondary diagnosis (for UC: ICD 9th revision 556 or ICD 10th revision K51; for CD: ICD 9th revision 555 or ICD 10th revision K50) after the return of the 1997 questionnaires in each cohort. The accuracy of ICD coding for the ascertainment of a number of chronic diseases, including IBD, for the inpatient component of the National Patient Register, has been validated previously, with a positive predictive value of 85% to 95%. 20 In addition, a recent validation study showed that the positive predictive values using this definition for CD, UC, and IBD cases were 81%, 90%, and 93%, respectively. 21 
Statistical Analysis
We examined the possibility that there was a nonlinear association between consumption of sweetened beverages and the risk of CD and UC using a previously reported nonparametic cubic spline method, 22 which also permits controlling for covariates and stepwise selection among spline variables. This analysis provides P values from the likelihood ratio tests for nonlinearity, a linear relation, and any relation. By using this method, the likelihood ratio tests comparing models with linear terms with those with spline terms were not statistically significant (all P comparisons > .48), indicating an absence of nonlinear associations between the consumption of sweetened beverages and the risk of CD and UC.
Person-time was calculated from January 1, 1998, to the date of diagnosis, emigration, death, or end of followup evaluation (January 1, 2015), whichever came first.
Categories of sweetened beverage consumption were created according to the number of servings, which best approximated quartiles of daily consumption (0, 0.1-0.4, 0.5-0.9, and 1 servings/d). We used Cox proportional hazard modeling to estimate the age-and multivariableadjusted hazard ratio (HR) and 95% CI. Our models were adjusted for age, body mass index (BMI), smoking, total caloric intake, total protein intake, total fiber intake, and nonsteroidal anti-inflammatory drug use (number of tablets/wk). In addition, all models were stratified by sex/cohort. Tests for trend across categories was performed by assigning the median value to each category and modeling this as a continuous variable.
We performed multiple sensitivity and exploratory analyses. First, we restricted our follow-up evaluation to after January 2002, excluding all IBD cases before this date, to allow for a 1-year lag between introduction of outpatient data in the National Patient Register and identification of prevalent cases of IBD previously not captured through hospitalizations. In addition, this analysis allowed us to explore the possibility that symptoms related to subclinical or early disease may have altered an individual's tendency to consume sweetened beverages. Second, we further adjusted our analysis for total sucrose intake, the primary sugar in sweetened beverages, to further examine the independent association between sweetened beverages and the risk of IBD. Finally, we examined the possibility that the association between sweetened beverages and the risk of IBD may be modified by age, sex, BMI, and smoking. We tested for the significance of the interaction by entering sweetened beverage consumption and these covariates in our models as multiplicative interaction terms. We also estimated the minimum detectable HR for CD and UC, assuming 80% power and an a of .05 using the described methods. 23 We tested for the proportional hazards assumption by examining the interaction between age in categories and sweetened beverage consumption in quartiles and observed no violations (all P > .65). We used SAS version 9.4 (Cary, NC) for these analyses. All P values were 2-sided and a value <.05 was considered statistically significant. The study was approved by the regional ethics committee of Stockholm, Sweden.
Results
Through the end of December 2014, we confirmed 349 incident cases of UC (incidence rate, 28 cases/ 100,000 person-years) and 143 incident cases of CD (incidence rate, 11 cases/100,000 person-years) among 83,042 participants over 1,264,345 person-years with a mean follow-up period of 11 years. The age at diagnosis of UC and CD cases ranged from 44 to 92 years. Baseline characteristics of participants are reported in Table 1 . The median age of participants at baseline was 60 years (range, 44-83 y). Compared with nonconsumers of sweetened beverages, participants with 1 or more servings per day were on average more likely to have used nonsteroidal anti-inflammatory drugs and had a higher caloric intake. However, there were no differences in age, BMI, smoking, total intake of protein, fiber, or fat comparing nonconsumers with participants in the highest quartile of sweetened beverage intake.
A higher consumption of sweetened beverages was not associated with an increased risk of UC (P trend ¼ .13) ( Table 2) . Compared with nonconsumers, the ageadjusted HR of UC among participants with 1 servings per day of sweetened beverages was 1.26 (95% CI, 0.93-1.69). These estimates were not materially altered after adjusting for other covariates (P trend ¼ .40). Compared with nonconsumers, the multivariable (MV)-adjusted HR of UC among participants with 1 servings per day of sweetened beverages was 1.14 (95% CI, 0.83-1.57). Similarly, we did not observe an association between a higher consumption of sweetened beverages and risk of CD (P trend ¼ .11) ( Table 2) . Compared with nonconsumers, the age-adjusted HR of CD among participants with 1 servings per day of sweetened beverages was 1.18 (95% CI, 0.72-1.73). These estimates Models are stratified by cohort (sex) and adjusted for age (years), BMI, smoking (never, past, and current), total caloric intake, total protein intake, total fiber intake, and nonsteroidal anti-inflammatory drug use.
were not materially altered after adjusting for other potential confounders (P trend ¼ .34). Compared with nonconsumers, the MV-adjusted HR of CD among participants with 1 servings per day of sweetened beverages was 1.02 (95% CI, 0.60-1.73). We also repeated our main analyses examining the risk of CD and UC among ever-users of sweetened beverages compared with nonusers and observed similar results. Compared with nonusers, ever-users had MV-adjusted HRs of 1.20 (95% CI, 0.85-1.69) for CD and 1.03 (95% CI, 0.83-1.28).
In our sensitivity analyses restricting our follow-up period to after January 2002, 1 year after the patient registry was expanded to include outpatient diagnoses, our results remained consistent (all P trend > .69). Compared with nonusers, the MV-adjusted HRs of CD and UC among participants with 1 servings per day were 0.82 (95% CI, 0.43-1.59) and 1.10 (95% CI, 0.75-1.61), respectively. We also explored the association between sweetened beverages and risk of CD and UC, independent of its primary sugar component by adjusting our models for total sucrose intake, and observed no significant associations. Compared with nonusers, the MV-adjusted HRs of CD and UC among participants with 1 servings per day were 1.13 (95% CI, 0.59-2.14; P trend ¼ .21) and 1.09 (95% CI, 0.74-1.61; P trend ¼ .67), respectively.
We explored whether the association between consumption of sweetened beverages and the risk of CD and UC were modified by age, sex (cohort), smoking, or BMI (Tables 3 and 4 ) and observed no evidence for effect modification (all P interaction > .12). Finally, we explored whether the association between sweetened beverages and the risk of UC was limited to participants with low fiber intake as shown in 1 prior study from the European Prospective Investigation into Cancer and Nutrition. Models are adjusted for age (years), cohort, BMI, smoking (never, past, and current), total caloric intake, total protein intake, total fiber intake, and nonsteroidal anti-inflammatory drug use. Models are adjusted for age (years), cohort, BMI, smoking (never, past, and current), total caloric intake, total protein intake, total fiber intake, and nonsteroidal anti-inflammatory drug use.
Among participants with a lower than median intake of fiber, the MV-adjusted risk of UC with each daily serving of sweetened beverage was 0.97 (95% CI, 0.85-1.11). In addition, there was no evidence of effect modification by fiber intake on the association between sweetened beverage intake and the risk of UC (P interaction ¼ .93). Finally, in analyses restricting diagnosis to elderly onset IBD (age, 60 y), we observed no associations between sweetened beverage and risk of CD or UC. Compared with nonusers, the MV-adjusted HRs of CD and UC for every 1 serving increase in sweetened beverages were 0.98 (95% CI, 0.85-1.14) and 1.05 (95% CI, 0.98-1.13), respectively.
Discussion
In 2 large prospective cohorts in Sweden, we found no association between consumption of sweetened beverages and the risk of CD or UC. The findings were consistent across several sensitivity analyses and among various subgroups.
Consumption of sweetened beverages has been linked previously to a number of metabolic syndromes including type 2 diabetes and cardiovascular disease. [4] [5] [6] 12 Much of these associations have been attributed to the presence of high sucrose, fructose, and corn syrup in sweetened beverages, which in turn are linked to weight gain and increased insulin resistance. The US Preventive Services Task Force has identified higher consumption of sweetened beverages as a dietary factor that at least in part explains the increasing rate of obesity in childhood and adolescence. 24, 25 More recently, a number of studies also have shown a link between consumption of sweetened beverages and higher levels of inflammatory markers such as C-reactive protein, interleukin 6, and tumor necrosis factor-receptor 2. 11, 12 Consistent with this observation, an analysis from the Nurses' Health Study showed that sugar-sweetened soda is associated with an increased risk of seropositive rheumatoid arthritis. 26 Interestingly, in that study the risk was particularly higher in those with later-onset disease (age, 55 y). Nevertheless, 2 randomized controlled trials have shown no association between sweetened beverages and measures of inflammatory markers including C-reactive protein and interleukin 6. 27, 28 In addition, a recent study by Kuzma et al 27 did not find any changes in measures of inflammation in adipose tissue with intake of sweetened beverages. These observations are in line with our finding of a lack of an association between sweetened beverages and the risk of CD or UC. Nevertheless, because the mean age of IBD diagnosis in our cohorts was older than 60 years, future studies examining the role of sweetened beverages in younger-onset CD and UC are needed to examine whether particular subgroups may be at risk. We acknowledge several limitations. First, at baseline we did not collect information on use of artificial sweeteners. However, based on the Swedish national consumption data, these beverages accounted for a small proportion of use in Sweden in 1997. We also did not have updated dietary data over the study period and therefore were not able to account for changes in patterns of use over the follow-up time. Nevertheless, the volume of sweetened-beverage consumption per capita in Sweden has not changed significantly after 1995. 29 Second, the age of diagnosis of all our participants was older than 40 and therefore our findings may not be generalized to earlier-onset IBD. Finally, our study may not have been powered to find a more modest association between sweetened beverage intake and risk of IBD. Nevertheless, we estimated that our study had more than 80% power to detect a minimum HR of 1.6 and 1.4 for CD and UC, respectively, figures that are significantly higher than previously observed associations between sweetened beverages and the risk of rheumatoid arthritis in the Nurses' Health Study (HR, 2.64; 95% CI, 1.56-4.46 for late-onset rheumatoid arthritis; and HR, 1.63; 95% CI, 1.15-4.46 for all rheumatoid arthritis cases). 26 In addition, specific dietary patterns that include high consumption of sweetened beverages may be associated with a risk of IBD, a possibility that was not explored in the current study.
Our study also had several strengths that are worth noting. First, the prospective nature of our study minimized the possibility of selection and recall biases inherent to case-control and retrospective cohort studies. Second, dietary data including sweetened beverages from SFFQ have been validated previously against dietary record with good to excellent coefficient correlation. Finally, in our analyses, we were able to account for other lifestyle factors and medications that potentially could have confounded the associations.
In 2 large prospective cohort studies we observed no evidence for strong or clinically meaningful associations between sweetened beverage intake and the risk of CD and UC. Whether sweetened beverages play a role in the development of earlier-onset IBD (age, <40 y) is unknown and should be the focus of future investigations.
